Roles of the urologist and nurse from the perspective of patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue therapy

被引:6
|
作者
Lebret, Thierry [1 ]
Bouregba, Alain [1 ]
机构
[1] Hop Foch, Dept Urol, F-92151 Suresnes, France
关键词
prostate cancer; hormonal therapy; LHRH agonist; professional-patient relations; multidisciplinary care; nurse-led services;
D O I
10.1111/j.1464-410X.2008.07785.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To establish the roles of the urologist, general practitioner (GP) and nurse from the perspective of the patient with prostate cancer receiving hormone therapy, and to assess patient satisfaction, in particular with management and information needs. PATIENTS AND METHODS Patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue (LHRH-a) therapy were recruited by a representative sample of 58 French urologists (March to April 2007) and invited to complete a 42-item questionnaire. RESULTS In all, 350 representative patients participated in the study; > 90% were totally or quite satisfied with the information given by their urologist at diagnosis and the start of treatment. Their main contact during treatment was with the nurse who gave the injection (84% of patients). The nurse's main role was to provide clarity (60% of patients), guidance (35%) and support to the family (28%). Fewer patients discussed disease stage and progression with their nurse (29%) than with a doctor (urologist, 63%; or GP, 61%). Fewer also discussed treatment (24% vs 32%) but as many patients discussed the impact of their disease and treatment with their nurse as with their doctor (e.g. 33% discussed general health and fatigue with the nurse, vs 26% with the urologist). The need for contact with a health professional was greater during the early stages of treatment. Patients treated for < 12 months with 3-monthly injections were less likely to be in favour of spacing injections than patients treated for >= 3 years. CONCLUSION The patient consults the urologist for reliable information on disease and treatment, and to the GP for further support, if needed, but the nurse has the pivotal role. A 3-monthly injection schedule enables regular face-to-face contact between the nurse and the patient and their family, and contributes towards the patient's coping strategies and quality of life.
引用
收藏
页码:1419 / 1424
页数:6
相关论文
共 50 条
  • [21] When and how to combine growth hormone with a luteinizing hormone-releasing hormone analogue
    Tanaka, T
    Satoh, M
    Yasunaga, T
    Horikawa, R
    Tanae, A
    Katsumata, N
    Tachibana, K
    Nose, O
    Hibi, I
    ACTA PAEDIATRICA, 1999, 88 : 85 - 88
  • [22] Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment
    Akaza, Hideyuki
    PHARMACOLOGY, 2010, 85 (02) : 110 - 120
  • [23] Luteinizing hormone-releasing hormone monotherapy: A viable option for treatment of prostate cancer?
    Schellhammer, PF
    UROLOGY, 2001, 58 (2A) : 10 - 15
  • [24] Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer
    Clinton, Timothy N.
    Woldu, Solomon L.
    Raj, Ganesh V.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (08) : 825 - 832
  • [25] Luteinising hormone-releasing hormone antagonists in prostate cancer therapy
    Msaouel, Pavlos
    Diamanti, Evanthia
    Tzanela, Marinela
    Koutsilieris, Michael
    EXPERT OPINION ON EMERGING DRUGS, 2007, 12 (02) : 285 - 299
  • [26] Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist
    Crawford, E. David
    Hafron, Jason M.
    Debruyne, Frans
    Wallis, Christopher
    Chang, Steven
    Garnick, Marc B.
    JOURNAL OF UROLOGY, 2024, 211 (01): : 63 - 70
  • [27] Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist
    Stira, Jordi
    Gravina, Carmen
    Lombardo, Riccardo
    De Nunzio, Cosimo
    JOURNAL OF UROLOGY, 2024, 211 (03):
  • [28] Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy
    Marumo, K
    Baba, S
    Murai, M
    INTERNATIONAL JOURNAL OF UROLOGY, 1999, 6 (01) : 19 - 23
  • [29] Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy
    Moreau, Jacques-Pierre
    Delavault, Patrick
    Blumberg, Joelle
    CLINICAL THERAPEUTICS, 2006, 28 (10) : 1485 - 1508
  • [30] Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer
    Raddin, Ryan S.
    Walko, Christine M.
    Whang, Young E.
    ANTI-CANCER DRUGS, 2011, 22 (03) : 299 - 302